This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.
In this study, a comparison of the exercise effects between individuals previously treated for specific lymphoma diagnoses and individuals with no history of cancer will be conducted. Therefore, in addition to a randomized controlled trial in individuals with a previous lymphoma diagnosis (i.e., exercise groups and a non-exercising control group), a reference group comprising age- and sex-matched individuals with no history of a cancer diagnosis will also be included. Participants in the reference group will undergo the same exercise intervention as the aerobic exercise group. This study recruits through invitation only. The primary endpoint in this study is the change in cardiorespiratory fitness, assessed as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, other variables derived from the cardiopulmonary exercise test and lung function assessments, and muscle cellular endpoints from muscle biopsies obtained from m. vastus lateralis, in addition to patient-reported outcomes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
280
Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
Norweigan School of Sport Sciences
Oslo, Norway
NOT_YET_RECRUITINGHelena Igelström
Uppsala, Sweden
RECRUITINGVO2peak
Peak oxygen uptake during a treadmill-based cardiopulmonary exercise test
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Systolic- and diastolic heart chamber dimensions
Cardiac morphology and function will be assessed by echocardiography (2D and 3D echocardiography and 2D strain echocardiography)
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Systolic- and diastolic longitudinal strain
Cardiac morphology and function will be assessed by echocardiography (2D and 3D echocardiography and 2D strain echocardiography)
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Lean body mass
Body composition will be assessed by dual x-ray absorptiometry
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Fat mass
Body composition will be assessed by dual x-ray absorptiometry
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Forced Vital Capacity
Lung function are assessed with spirometry.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Forced Expiratory Volume 1 sec
Lung function are assessed with spirometry.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Maximal voluntary ventilation
Lung function are assessed with spirometry.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Diffusion capacity
Diffusion capacity for carbon monoxide is assessed with single breath diffusion capacity test.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Physical activity
Actigraph accelerometer with physical activity diary. 7 days consecutive measurement at each timepoints.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Physical activity
Patient reported physical activity is assessed with Godin Leisure-Time Exercise Questionnaire
Time frame: Baseline, 10-12 weeks from baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Global Health related Quality of life
Patient reported health related quality of life will be assessed with EORTC QLQ C 30
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Blood volume
Will be assessed in Norway only. Using the carbon monoxide rebreathing method.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Muscle fiber area
Will be assessed in Norway only. Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Time frame: Baseline, five months from baseline (i.e. end of intervention)
Muscle fiber type
Will be assessed in Norway only. Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Time frame: Baseline, five months from baseline (i.e. end of intervention)
Muscle mitochondria mass
Will be assessed in Norway only. Change in mitochondrial proteins will be assessed in muscle biopsies using western blot
Time frame: Baseline, five months from baseline (i.e. end of intervention)